Abstract:Obesity remains a significant global health challenge, with bariatric surgery remaining as one of the most effective treatments for severe obesity and its related comorbidities. This review highlights the multifaceted impact of bariatric surgery beyond mere physical restriction or nutrient malabsorption, underscoring the importance of the gut microbiome and neurohormonal signals in mediating the profound effects on weight loss and behavior modification. The various bariatric surgery procedures, such as Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), act through distinct mechanisms to alter the gut microbiome, subsequently impacting metabolic health, energy balance, and food reward behaviors. Emerging evidence has shown that bariatric surgery induces profound changes in the composition of the gut microbiome, notably altering the Firmicutes/Bacteroidetes ratio and enhancing populations of beneficial bacteria such as Akkermansia. These microbiota shifts have far-reaching effects beyond gut health, influencing dopamine-mediated reward pathways in the brain and modulating the secretion and action of key gut hormones including ghrelin, leptin, GLP-1, PYY, and CCK. The resultant changes in dopamine signaling and hormone levels contribute to reduced hedonic eating, enhanced satiety, and improved metabolic outcomes. Further, post-bariatric surgical effects on satiation targets are in part mediated by metabolic byproducts of gut microbiota like short-chain fatty acids (SCFAs) and bile acids, which play a pivotal role in modulating metabolism and energy expenditure and reducing obesity-associated inflammation, as well as influencing food reward pathways, potentially contributing to the regulation of body weight and reduction in hedonic eating behaviors. Overall, a better understanding of these mechanisms opens the door to developing non-surgical interventions that replicate the beneficial effects of bariatric surgery on the gut microbiome, dopamine signaling, and gut hormone regulation, offering new avenues for obesity treatment.

From Bariatric to Metabolic Surgery: Definition of a New Discipline and Implications for Clinical Practice

Small intestine-targeted endoscopic bariatrics: current status and future perspectives.

Barriers to metabolic surgery and how to address them

Bariatrics and endoscopic therapies for the treatment of metabolic disease: Past, present, and future

Updates in Bariatric Surgery

Targeting FXR and FGF19 to Treat Metabolic Diseases—Lessons Learned From Bariatric Surgery

From surgery to endoscopy: the evolution of the bariatric discipline

A perspective on metabolic surgery from a gastroenterologist

Metabolic Bariatric Surgery and Type 2 Diabetes Mellitus: an Endocrinologist's Perspective

Bariatric surgery of T2DM:evidence and position

Clinical Perspectives, Eligibility, and Success Criteria for Bariatric/Metabolic Surgery

Future Prospects of Metabolic and Bariatric Surgery: A Comprehensive Review

Novel Surgical Interventions for the Treatment of Obesity

Diabetes and obesity: A debate on bariatric interventions and its implications

Bariatric Surgery: Current Trends and Newer Surgeries

Glucose metabolism after bariatric surgery: implications for T2DM remission and hypoglycaemia

Effect of Bariatric Surgery on Metabolic Diseases and Underlying Mechanisms

Bariatric surgery and diabetes: Current challenges and perspectives

Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?

Metabolic-Bariatric Surgery for Type 2 Diabetes: Time(ing) for a Change

Influence of Bariatric Surgery on Gut Microbiota Composition and Its Implication on Brain and Peripheral Targets